World Enough and Time:
The Science, Politics and Ethics of Longevity Medicines

Can we develop drugs to slow the aging process, keeping people alive, healthy, and vigorous well beyond their current life expectancy? Progress in basic aging research has suggested that aging can indeed be slowed, and has provided good clues about how we might develop new medications that protect us from multiple diseases of aging.

If we develop the means to tweak the aging process, does that mean we should? Why do some people fear aging research, at the same time that they vigorously champion research on healthy lifestyles and disease prevention? What would it be like to live in a society where the average 100-year-old was as healthy and active as today's typical 70-year-old?

The American Federation for Aging Research recently hosted the second of a multi-part media luncheon series to explore these issues. Richard Miller, MD, PhD, Associate Director for Research at the University of Michigan Geriatrics Center, discussed how research on aging is advancing to the point where these ethical concerns come into play.

For more information, please contact us at 212-703-9977 or info@afar.org.

Funding for the media luncheon series was made possible through an unrestricted educational grant from Pfizer Inc.

Dr. Rich Miller with Marilyn Balamaci and Fran Carpenter, both of PARADE Magazine

Dr. Rich Miller with Catherine Arnst of BusinessWeek